Mst Continus (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Mst Continus, is an opioid analgesic presented as an oral formulation for oral use. It is prescribed to manage moderate to severe pain in adult patients when other analgesics are insufficient, including acute postoperative pain, cancer‑related pain, and chronic severe pain conditions.

GNH USA supplies Mst Continus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for healthcare providers across the European market and beyond.

Morphine Sulfate is an opioid analgesic used to treat pain conditions across several clinical pathways.

- Acute postoperative pain: provides rapid analgesia to facilitate recovery after surgery. - Cancer pain: offers strong relief for malignant disease–related pain. - Chronic severe pain: manages long‑term severe nociceptive pain when other treatments are inadequate.

Morphine Sulfate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: feeling of sickness often accompanied by an urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or unsteadiness. - Itching: mild skin pruritus, especially on the face or neck. - Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Anaphylactic reaction: sudden, severe allergic response with rash, swelling, and airway compromise. - Adrenal insufficiency: inadequate cortisol production leading to fatigue and weakness. - Seizures: uncontrolled electrical activity in the brain. - Coma: profound loss of consciousness.

When prescribing or dispensing Morphine Sulfate, several safety considerations should be observed.

- Assess pain severity: confirm that opioid therapy is appropriate for the level of pain. - Evaluate respiratory function: monitor for signs of respiratory depression, especially in opioid‑naïve patients. - Monitor for dependence: watch for signs of tolerance, misuse, or addiction during long‑term therapy. - Use caution in renal or hepatic impairment: dose adjustments may be required. - Adjust dose in elderly patients: start with lower doses and titrate slowly. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Morphine Sulfate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, alcohol): may cause profound sedation or respiratory depression. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome and severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise morphine plasma levels, heightening toxicity. - Other opioids: additive respiratory depression and sedation. - Respiratory depressants (e.g., barbiturates): potentiate breathing suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce morphine effectiveness. - Diuretics: can enhance orthostatic hypotension. - Antihistamines: may increase sedation. - Certain antidepressants (e.g., SSRIs): may modestly raise serotonin levels. - Antihypertensives: monitor blood pressure for additive hypotensive effects.